Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05276973 · ClinicalTrials.gov registry record · Phase 1
Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer
A Phase 1 study of Ovarian Endometrioid Adenocarcinoma and Fallopian Tube Endometrioid Adenocarcinoma, sponsored by National Cancer Institute (NCI).
- Active
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
- 8
- Study locations
NCT05276973 is a Phase 1 study of Ovarian Endometrioid Adenocarcinoma and Fallopian Tube Endometrioid Adenocarcinoma that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 25 participants, below the 300-participant average among 15 other Ovarian Endometrioid Adenocarcinoma trials with a reported enrollment target (92% lower). The trial reports 8 study locations across 8 states.
The verdict
NCT05276973, a Phase 1 study of Ovarian Endometrioid Adenocarcinoma and Fallopian Tube Endometrioid Adenocarcinoma, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
- 8
- Study locations
Study Summary
This phase I/IB trial tests the safety, side effects, and best dose of ipatasertib in combination with paclitaxel and carboplatin in treating patients with stage III or IV epithelial ovarian cancer. Ipatasertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Paclitaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Giving ipatasertib in combination with paclitaxel and carboplatin may lower the chance of the tumor growing or spreading for longer than the paclitaxel and carboplatin alone.
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Ipatasertib
- PROCEDURE Biopsy
- DRUG Paclitaxel
Study Locations (8)
California
- UCSF Medical Center-Mission Bay - San Francisco
Georgia
- Augusta University Medical Center - Augusta
Ohio
- Cleveland Clinic Foundation - Cleveland
Oklahoma
- University of Oklahoma Health Sciences Center - Oklahoma City
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
Rhode Island
- Women and Infants Hospital - Providence
Virginia
- Virginia Commonwealth University/Massey Cancer Center - Richmond
Wisconsin
- Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2022-09-08 |
| Est. Completion | 2026-02-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05276973
The ClinicalTrials.gov registry entry for NCT05276973 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 300-participant average among 15 other Ovarian Endometrioid Adenocarcinoma trials with a reported enrollment target (92% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Ovarian Endometrioid Adenocarcinoma appearing as the primary indexed condition, and to 4 interventions - of which Carboplatin is the first listed.
NCT05276973 reports 8 study locations spanning 8 distinct geographic areas - top geographies include California, Georgia, Ohio.
Frequently Asked Questions
What is clinical trial NCT05276973 about?
NCT05276973 is a clinical study titled "Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer". This phase I/IB trial tests the safety, side effects, and best dose of ipatasertib in combination with paclitaxel and carboplatin in treating patients with stage III or IV epithelial ovarian cancer. Ipatasertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth...
What is the current status of trial NCT05276973?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2022-09-08. Estimated completion is 2026-02-26.
What conditions does trial NCT05276973 study?
This clinical trial studies the following conditions: Ovarian Endometrioid Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Stage III Ovarian Cancer AJCC v8, Fallopian Tube High Grade Serous Adenocarcinoma.
What interventions are being tested in trial NCT05276973?
The interventions under investigation include: Carboplatin (DRUG), Ipatasertib (DRUG), Biopsy (PROCEDURE), Paclitaxel (DRUG).
Who is sponsoring clinical trial NCT05276973?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05276973 being conducted?
This trial has 8 study locations across California, Georgia, Ohio, Oklahoma, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Endometrioid Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer
ACTIVE NOT RECRUITING · Phase 1
-
TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer
RECRUITING · Early Phase 1
-
Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
RECRUITING · Phase 3
Explore more on PlainTrial
Ovarian Endometrioid Adenocarcinoma
All registered trials for this condition
Fallopian Tube Endometrioid Adenocarcinoma
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.